Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial showsBy Press Room20 December 2024 Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company AstraZeneca, showed meaningful improvements in…
Confronting The Silent Threat Of Eye CancerBy Press Room1 March 2024 This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a…